US 12,129,264 B2
Crystalline forms of a PAR4 inhibitor
Roxana F. Schlam, Hod Hasharon (IL); Nicolas Cuniere, Belle Mead, NJ (US); Victoria A. Mbachu, Somerset, NJ (US); Zhongping Shi, Plainsboro, NJ (US); and Petinka I. Vlahova, West Lafayette, IN (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 17/415,237
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
PCT Filed Dec. 20, 2019, PCT No. PCT/US2019/067717
§ 371(c)(1), (2) Date Jun. 17, 2021,
PCT Pub. No. WO2020/132381, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/783,223, filed on Dec. 21, 2018.
Prior Publication US 2022/0064186 A1, Mar. 3, 2022
Int. Cl. C07D 513/04 (2006.01); A61K 31/433 (2006.01); A61K 45/06 (2006.01); A61P 7/02 (2006.01); C07C 55/10 (2006.01); C07C 59/265 (2006.01)
CPC C07D 513/04 (2013.01) [A61K 31/433 (2013.01); A61K 45/06 (2013.01); A61P 7/02 (2018.01); C07C 55/10 (2013.01); C07C 59/265 (2013.01); C07B 2200/13 (2013.01)] 16 Claims
 
1. A co-crystal of the compound of Formula (1)

OG Complex Work Unit Chemistry
and a co-former, wherein the co-former is succinic acid or citric acid.